The development of costs for antidiabetics in statutory and private health insurance in Germany — an analysis of selected influencing factors

ConclusionEven though there is a different growth rate, the cost development for antidiabetics in both collectives illustrates the health economic relevance of this clinical picture and shows the necessity for a detailed analysis of drug expenditure. Further research approaches that investigate cost influences caused by concomitant or secondary diseases as well as secondary damage of diabetes mellitus can make an additional contribution to the long-term financial viability of the health care system.
Source: Journal of Public Health - Category: Health Management Source Type: research